N-[4-(4-Bromobenzenesulfonyl)phenyl]-3-chlorobenzamide

Catalog No. :
ACGAYR347
CAS No. :
339031-54-8
Molecular Formula :
C19H13BrClNO3S
Molecular Weight :
450.74

IUPAC Name:N-(4-((4-bromophenyl)sulfonyl)phenyl)-3-chlorobenzamide

N-[4-(4-Bromobenzenesulfonyl)phenyl]-3-chlorobenzamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-[4-(4-Bromobenzenesulfonyl)phenyl]-3-chlorobenzamide
IUPAC NameN-(4-((4-bromophenyl)sulfonyl)phenyl)-3-chlorobenzamide
MDL No.MFCD00172335
Molecular FormulaC19H13BrClNO3S
Molecular Weight450.74
SMILESO=C(NC1=CC=C(S(=O)(C2=CC=C(Br)C=C2)=O)C=C1)C3=CC=CC(Cl)=C3
InChI KeyZBIMFUSHOIIBJV-UHFFFAOYSA-N
SynonymN-(4-[(4-BROMOPHENYL)SULFONYL]PHENYL)-3-CHLOROBENZENECARBOXAMIDE;N-[4-(4-bromobenzenesulfonyl)phenyl]-3-chlorobenzamide;N-[4-[(4-Bromophenyl)sulfonyl]phenyl]-3-chlorobenzamide;Benzamide, N-[4-[(4-bromophenyl)sulfonyl]phenyl]-3-chloro-
CAS No.339031-54-8

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACGAYR347 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGAYR347 route product structure diagram
    ACGAYR347339031-54-8
Inquiry

2. ACGAYR347 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACZDCA319 route compound structure diagram
    ACZDCA319535-80-8 In Stock
  4. Then
  5. ACGAYR347 route product structure diagram
    ACGAYR347339031-54-8
Inquiry

Comments (0)